Typewriter Therapeutics, a Cambridge, Massachusetts-based biotechnology startup, has raised $56 million in Series A funding to advance its non-viral gene therapy platform toward clinical development.

The round was led by RA Capital Management and AN Venture Partners, with participation from ANRI, Gemseki, and SBI US Gateway Fund.

Led by CEO Matthew Stanton, Typewriter Therapeutics is developing a gene-writing platform based on target-primed reverse transcription (TPRT) and the natural R2 retrotransposon system. The technology uses an RNA-based approach delivered through lipid nanoparticles (LNPs) to insert therapeutic genes into specific locations in the genome.

The company is initially focusing on in vivo CAR-T therapies and hereditary liver diseases. Its goal is to develop treatments that can deliver therapeutic genes directly inside the body, potentially reducing some of the manufacturing challenges associated with traditional cell and gene therapies.

Its platform is designed to be non-viral and repeatable, offering a different approach to gene delivery compared with viral vector-based technologies.

The company believes its technology could help address manufacturing costs and safety challenges associated with some existing gene therapy approaches.

With the new funding, Typewriter plans to expand its operations and research and development efforts. The company expects to begin non-human primate studies in late 2026 and establish its first development candidate for an in vivo CAR-T program.

The funding comes as the biotech industry continues to explore non-viral gene delivery and in vivo CAR-T technologies. These approaches are attracting interest because they could simplify treatment and reduce some of the manufacturing complexity associated with therapies produced outside the body.

Typewriter Therapeutics will use the Series A capital to further develop its TPRT platform and move its lead programs closer to potential clinical testing.